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Abstract 
Oxidation-associated malondialdehyde (MDA) modification 
of proteins can generate immunogenic neo-epitopes that 
are recognized by autoantibodies. In health, IgM antibodies 
to MDA-adducts are part of the natural antibody pool, while 
elevated levels of IgG anti-MDA antibodies are associated 
with inflammatory and autoimmune conditions. Yet, in 
human autoimmune disease IgG anti-MDA responses have 
not been well characterized and their potential contribution 
to disease pathogenesis is not known. Here, we investigate 
MDA-modifications and anti-MDA-modified protein 
autoreactivity in rheumatoid arthritis (RA). While RA is 
primarily associated with autoreactivity to citrullinated 
antigens, we also observed increases in serum IgG anti-
MDA in RA patients compared to controls. IgG anti-MDA 
levels significantly correlated with disease activity by 
DAS28-ESR and serum TNF-alpha, IL-6, and CRP. Mass 
spectrometry analysis of RA synovial tissue identified 
MDA-modified proteins and revealed shared peptides 
between MDA-modified and citrullinated actin and 
vimentin. Furthermore, anti-MDA autoreactivity among 
synovial B cells was discovered when investigating 
recombinant monoclonal antibodies (mAbs) cloned from 
single B cells, and 3.5 % of memory B cells and 2.3% of 
plasma cells were found to be anti-MDA positive. Several 
clones were highly specific for MDA-modification with no 
cross-reactivity to other antigen modifications such as 
citrullination, carbamylation or 4-HNE-carbonylation. The 
mAbs recognized MDA-adducts in a variety of proteins 
including albumin, histone 2B, fibrinogen and vimentin. 
Interestingly, the most reactive clone, originated from an 
IgG1-bearing memory B cell, was encoded by near 
germline variable genes, and showed similarity to 
previously reported natural IgM. Other anti-MDA clones 
display somatic hypermutations and lower reactivity. 
Importantly, these anti-MDA antibodies had significant in 
vitro functional properties and induced enhanced 
osteoclastogenesis, while the natural antibody related high-
reactivity clone did not. We postulate that these may 
represent distinctly different facets of anti-MDA 
autoreactive responses.  
Keywords: Autoimmunity, oxidation, malondialdehyde 
acetaldehyde modification, natural autoantibodies, 
rheumatoid arthritis 
 
Highlights:  
* Malondialdehyde modification of self-proteins occurs in 
the RA joint  
* IgG anti-MDA reactivity is elevated in RA and associated 
with disease activity 
* Specific anti-MDA reactive synovial B cells have been 
recovered from RA patients 
* Different classes of IgG anti-MDA reactivity exists 
* Some anti-MDA IgG enhance osteoclastogenesis  
1. Introduction 
Rheumatoid arthritis (RA) is a chronic and potentially 
disabling autoimmune disease affecting between 0.5 and 
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1% of the Western population [1]. RA is associated with 
synovial inflammation and progressive destruction of joints. 
There is also increased risk for morbidity and mortality from 
accelerated atherosclerotic cardiovascular disease [2]. 
Pathogenesis is associated with a characteristic 
autoimmune response to self-proteins post-translationally 
modified by citrullination, resulting in circulating anti-
citrullinated protein antibodies (ACPA) that are detected in 
65-80% of patients with established disease [3] (reviewed 
in [4]).  
Seropositive RA is defined by clinical criteria that include 
the presence of IgG antibodies to synthetic peptides, 
termed cyclic citrullinated peptides (CCP), and/or IgM 
rheumatoid factors (RF) that bind aggregated IgG Fc 
regions [5]. Yet RA patients also commonly display other 
autoantibodies, including IgG binding to proteins post-
translationally modified by carbamylation, that involves the 
generation of homocitrulline residues from lysines [6, 7]. 
Antibodies to carbamylated antigens have been reported in 
both seropositive and seronegative RA patients. They can 
arise in parallel to ACPA responses and could at times 
reflect unique epitope recognition, but may also be partly 
explained by ACPA cross-reactivity [8].  
The current report focuses on the contribution of immune 
responses to a distinctly different and less extensively 
studied self-protein modification, malondialdehyde (MDA) 
adducts, during RA pathogenesis.  
MDA is a naturally occurring, highly reactive aldehyde, 
produced under oxidative stress states associated with 
excessive generation of reactive oxygen species (ROS). 
Elevated ROS catalyzes membrane lipid peroxidation and 
the formation of reactive MDA that can covalently modify 
proteins through carbonylation of amino acids carrying free 
amine groups (i.e. lysine, arginine, histidine), and to less 
extent amino acids with amide groups (i.e. asparagine, 
glutamine), which can generate structural changes and 
neo-epitopes [9, 10]. A large number of self-proteins have 
been found to be modified by MDA under local 
inflammatory conditions, including vimentin, fibrinogen, a-
enolase and albumin [11, 12] (reviewed in [13, 14]). 
Acetaldehyde (AcA) can further react with MDA adducts to 
form immunogenic malondiadehyde-acetaldehyde (MAA) 
modifications (Figure 1) [15]. ROS levels sufficient to cause 
tissue injury can be generated by exogenous stimuli such 
as tobacco smoke, or be endogenously produced during 
inflammation [16]. Moreover, oxidized proteins and lipids 
are also formed as a consequence of programmed death 
pathways and the resulting adducts on apoptotic cells can 
be recognized by some anti-MDA antibodies [17-19].  
Recent evidence implicates that autoimmune diseases are 
associated with an altered redox-state and elevated levels 
of oxidative species, which may contribute to disease 
pathogenesis [20-25]. Increased levels of MDA and MDA-
modified proteins, observed both in systemic lupus 
erythematosus (SLE) and RA, may reflect disturbances in 
oxidation balance occurring during systemic inflammation 
[20-25]. Strikingly, at birth the human natural IgM repertoire 
has a strong bias towards antibody-recognition of 
oxidation-associated epitopes, especially MDA-
modifications [18, 19, 26]. Hence, the immune system is 
primed from birth to recognize modified self-antigens, and 
it has been postulated that these antibodies play important 
roles in clearance of apoptotic cells, neutralization of 
harmful molecules, and maintenance of immune 
homeostasis [27]. However, whilst IgM may be protective, 
the constant regions of IgG autoantibodies with the same 
specificity may instead trigger inflammatory responses. IgG 
autoantibodies that bind MDA can be elevated in SLE, and 
levels are directly related to increased disease activity [25, 
28].  
Herein, we have investigated the representation of MDA-
modifications of self-proteins in the rheumatoid joint and 
their potential as immunogens for eliciting immune 
responses. In a cross-sectional RA cohort, we also 
evaluated serological levels of autoantibodies to MDA-
modified self-protein epitopes in relation to disease activity. 
Furthermore, we recovered human mAbs isolated from 
individual synovial B cells and plasma cells from RA 
patients, and evaluated their binding specificity for MDA-
modified self-proteins and their associated in vitro 
functional properties.  
2. Material and Methods 
2.1 Patients and sample procedures 
All RA patients fulfilled the 2010 ACR/EULAR criteria for 
diagnosis [5], and informed consent was obtained for all 
patients and controls according to protocols approved by 
the Human Subjects Institutional Review Board of NYU 
School of Medicine, the Ethics Review Committee at the 
University of Birmingham, and the Ethics Review 
Committee North at the Karolinska University Hospital. 
Patients were classified as seropositive RA and 
seronegative RA based on the clinical CCP2 assay. 
Synovial fluid samples for cell isolation were collected in 
connection to when the patients required arthrocentesis 
due to local disease activity, and the patients were given 
subsequent local steroid injections. Synovial tissues of RA 
patients or disease controls were obtained at the time of 
joint-replacement surgery.  
 
2.2 Mass spectrometry analysis 
In vitro MDA-modified BSA was analyzed in pilot studies for 
MDA-detection and for comparison between different MDA-
modification times. Ten µg protein was reduced and 
alkylated by DTT and iodoacetamide (Sigma Aldrich), 
precipitated and digested by trypsin (sequencing grade, 
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Promega) in 50 mM ammonium bicarbonate and 30% 
DMSO (Sigma Aldrich) at protease to protein concentration 
of 1:20, as previously described [29]. After desalting the 
peptides using C18 StageTips (Thermo Fisher Scientific), 
the peptides were analyzed by nanoLC-MS/MS a 
NanoUltimate 3000 coupled on-line to an LTQ Orbitrap 
Velos mass spectrometer, were the Velos Orbitrap had 
been upgraded to an Elite (Thermo Fisher Scientific, 
Germany). The peptides were separated using a Acclaim® 
PepMap100 precolumn (C18, 3 μm, 100 Å; Thermo 
Scientific) together with a 15 cm EASY-Spray PepMap® 
analytical column (C18, 3µm, 100Å; Thermo Scientific). 
The separation was achieved using ACN/water gradients 
(buffer A: 2% ACN, 0.1% FA; buffer B: 98% ACN, 0.1% 
FA) of 5–26% B over 55 min, followed by a 26–95% ACN 
gradient over 5 min and 95% ACN for 8 min, all at a flow 
rate of 300 nl/min. The instruments were operated in a 
data-dependent mode with a top 5 method. The mass 
spectra were acquired at a resolution of 60,000 followed by 
either CID only or HCD only MS/MS fragmentation. A 
normalized collision energy of 35 was used for CID and 30 
for HCD. The HCD MS/MS spectra were acquired at a 
resolution of 15,000. One pmol of the three samples were 
analyzed by both MS analysis using CID only and HCD 
only, each in two technical replicates (i.e. four analyses per 
samples). 
Data from an earlier reported study of post-translational 
citrullination in rheumatoid synovial tissue [30], were re-
searched for the detection of MDA-modified proteins. As 
primary analyses sought to detect citrullinated peptides the 
samples were enzymatically processed with Lys-C to avoid 
digestion at arginine sites. Note that this will reduce the 
detection of lysine modified residues. As previously 
described, each synovial tissue sample was analyzed by 
four different MS methods: top5 using CID/ETD 
fragmentation, top5 using ETD only, top4 using HCD only, 
and top4 using an inclusion list together HCD only (the 
inclusion list contained citrullinated peptides identified in 
the same study). The 28 raw files [30] were re-processed 
by Raw2MGF v2.1.3 and re-searched against the human 
complete proteome database (downloaded from 
www.uniprot.org April, 2013; 71434 sequences; 24507501 
residues). At least one spectrum from each peptide 
reported in the supplementary Table 1 and 2 was validated 
manually. 
 
2.3 Single cell cloning of synovial B cells and 
preparation of human monoclonal antibodies 
Monoclonal antibodies (mAbs) from single synovial 
memory B cells or plasma cells were generated as recently 
described [31-33]. Notably, the current study includes 
additional patient samples than previously published. 
Briefly, cryopreserved synovial mononuclear cells were 
thawed, stained with specific fluorescently labeled 
antibodies, and flow cytometric sorted as either; single 
CD19 FcRL4+/- B cells [31, 34], or CD19+ IgG+ cells [32], 
into 96-well plates containing 5 μl per well of 0.5x PBS 10 
mM DTT and RNAsin (RNAase inhibitor; Promega). For 
isolation of single synovial antibody secreting cells 
(plasmablasts/plasma cells), the fluorescent foci method 
[35] was applied using anti-human IgG specific beads and 
FITC labeled anti-human IgG (gamma-specific), to identify 
all IgG secreting cells in the synovial sample by fluorescent 
microscopy [33]. Cells that displayed an IgG fluorescent 
halo were extracted using an Eppendorf NK 
micromanipulator, and single-cell cloning was then 
performed, with the same protocol used for flow cytometry 
sorted memory B cell [32]. Immunoglobulin variable genes 
were cloned into human heavy- and light-chain IgG 
expression vectors, after cDNA synthesis and PCR 
amplification, using established methods [32, 36]. 
Recombinant mAbs were expressed as IgG1 in the 
Expi293 system (Thermo Fisher Scientific) with transient 
transfection using PEI-max (total 38 μg plasmid DNA to 30 
ml cells, IgH and IgL constructs). Antibodies were purified 
using protein G affinity purification (Protein G Fast Flow 
Sepharose, GE Healthcare Life Sciences) and their 
concentrations determined by IgG ELISA. Selected mAbs 
were also produced in larger scale (i.e. 400-3200 ml 
cultures), with purified products subsequently 
characterized with quality testing that included SEC 
analysis for aggregation, SDS-PAGE, specificity ELISA, 
and endotoxin testing.  
 
2.4 Antigen-specificity assays for serum and 
monoclonal antibodies 
Serological screenings of specific IgG and IgM antibody 
levels in clinical samples were performed using previously 
reported methods [28, 37]. Wells were coated with MDA-
BSA (Academy Bio-Medical) or PC-BSA (low load, 
Biosearch Technologies) at 3 μg/ml, blocked with 3% BSA 
in PBS, and serum samples were diluted 1:200 and 
1:1000. IgG, IgA or IgM reactivity was detected with HRP-
conjugated gamma-specific goat (Fab’)2 anti-human IgG, 
goat anti-human IgA (Jackson ImmunoResearch) or mu-
specific goat anti-human IgM (Southern Biotech), and 
developed with TMB substrate (Biolegend). All absorbance 
values were quantified towards a serum reference sample 
and presented as Relative Units (RU)/ml. Serum 
rheumatoid factor and anti-CCP3 levels were determined 
using clinical assays, (QUANTA lite RF IgM and CCP3), 
according to the manufacturer’s instructions (Inova 
Diagnostics). For IgM and IgA anti-CCP3 reactivity, plates 
were coated with CCP3 peptide at 3 μg/ml (gift from Inova 
Diagnostics) and reactivity was detected using HRP-
conjugated goat anti-human IgM (Southern Biotech) or 
goat anti-human IgA (Jackson ImmunoResearch). 
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Similarly, mAbs were screened for MDA reactivity at 3 
ug/ml using an adapted assay from above. All mAbs were 
also screened for non-specific binding to unmodified BSA 
(molecular grade BSA, NEB) and RF activity using wells 
coated with chromopure rabbit IgG (Jackson 
ImmunoResearch), and binding detected with HRP-
conjugated rabbit (Fab’)2 gamma-specific anti-human IgG 
(Jackson ImmunoResearch). Reactivity of selected clones 
to other antigens, carbamylated BSA, 4-HNE-modified 
BSA, MDA-LDL, LDL (Academy Bio-Medical) and PC-BSA 
(Biosearch Technologies), were similarly determined by 
ELISA. 
For antigen competition assays and Western Blot analysis 
of mAb specificity, we produced MDA-BSA samples with 
different levels of modification. Briefly, MDA was generated 
by acid hydrolysis of tetramethoxypropane (Sigma Aldrich), 
thereafter molecular grade BSA (NEB) at 1 mg/ml was 
modified by 50 mM MDA in PBS (pH 7.4) for 2-24 hrs at 
37°C, followed by extensive dialysis to PBS. For 
generation of higher level of MAA-type modifications, 
acetaldehyde was added to 25 mM to the 2 hrs MDA-
reaction. For ELISA competition studies, 100 ng/ml mAb 
IgG was mixed with indicated concentration of antigens in 
1% BSA in PBS, incubated for 15 min at 37°C, and 
subsequently analyzed for binding to commercial MDA-
BSA, as above. For SDS-PAGE and Western blot analysis, 
3 μg of different lots of MDA-BSA or control-treated BSA 
were reduced and separated on Bolt Bis-Tris 4-12% gels 
with MES-SDS running buffer and blotted to PVDF 
membrane according to the manufacturer’s instructions 
(ThermoFisher Scientific). The membrane was blocked 
with 3% BSA and stained with 1 μg/ml 1276:01F04 4°C 
o/n, followed by detection with biotinylated goat (Fab’)2 
anti-human IgG (Jackson ImmunoResearch) and anti-
biotin-HRP (Cell Signaling Technology). Binding was 
detected by chemiluminescence using Clarity Western ECL 
Substrate (BioRad). 
For ELISA studies of purified human fibrinogen (Sigma 
Aldrich), human serum albumin (HSA, Sigma Aldrich)), 
purified bovine histone 2B (Immunovision), or recombinant 
human vimentin (kind gift from Dr Karl Skriner, Charité 
Universitätsmedicin, Berlin), the antigens were coated at 3 
ug/ml and MDA-modified on the surface for 2 hrs at 37°C 
by adding 100 mM MDA in PBS, followed by washing and 
blocking. Citrullination of fibrinogen and histone 2B was 
performed in 100 mM Tris, 10 mM CaCl2, 5 mM DTT, with 
PAD4 (Cayman Chemicals, 0.75 U/mg protein), 37°C 2 
hrs, followed by dialysis to PBS. Vimentin was similarly 
citrullinated using rabbit PAD (Sigma Aldrich). 
All mAbs were also screened for binding to citrullinated 
peptide antigens using an antigen microarray solid-phase 
allergen chip multiplex assay (ISAC) with paired 
citrullinated and arginine-containing peptides, as well as 
other control antigens (Phadia AB, Uppsala, Sweden) [38] 
(Supplemental Table 5, Supplemental Figure 9). Reactivity 
to the diagnostic peptide CCP3 was in addition tested for 
mAbs at 5 ug/ml with the QUANTA lite CCP3 assay (Inova 
Diagnostics).  
 
2.5 Inflammatory biomarkers 
Serum concentrations of inflammatory biomarkers and 
cytokines (IL-17F, IL-1b, TNF-a, IL-6Ra, IL-6, VEGF, 
sTNFRII and CRP) in the DMARD naïve cohort was 
determined using the highly sensitive Singulex 
Immunoassay System (Singulex, Inc., Alameda, CA) [39].  
 
2.6 Osteoclast stimulation assay 
Peripheral blood mononuclear cells (PBMCs) were isolated 
from healthy blood donor buffy coat by ficoll separation 
(Lymphoprep; Axis Shield, Norway) and monocytes were 
positively selected using anti-CD14 microbeads (Miltenyi 
Biotec). CD14-positive monocytes were seeded in 96-well 
plates 1x10^5 per well in 200 μl and differentiated into 
macrophages in Dulbecco's modified Eagle medium 
(DMEM) supplemented with 25 ng/mL macrophage colony-
stimulation factor (M-CSF) (Peprotech). After every 3 days 
half of the medium replaced supplemented with 30 ng/mL 
M-CSF, 2 ng/mL RANKL (R&D Systems) along with 1 
μg/ml or 10 μg/ml mAbs. The osteoclast (OC) culture was 
stopped after 8 days treatment. OCs were stained using 
tartrate-resistant acid phosphatase (TRAP) staining 
(leucocyte acid phosphatase kit 387A, Sigma-Aldrich) and 
analyzed. TRAP-positive cells with at least three nuclei 
were counted as OCs using a light microscope. In parallel, 
the OCs were generated in synthetic calcium phosphate 
surface (Corning) for 14 days and the surface area eroded 
was analyzed by the NIS-elements from Nikon 
(BergmanLabora). 
 
2.7 Immunohistochemistry 
Binding of anti-MDA mAbs to synovial tissue was 
evaluated by immunohistochemistry. In brief, 2% 
formaldehydefixed 7-μm–thick cryostat sections of 
synovial biopsy tissue were washed and permeabilize by 
PBS/saponin (0.1%, pH 7.4). Tissue sections were blocked 
with 1 % hydrogen peroxide 50 mins, followed by 30 min 3 
% BSA 5 μg/ml human Fc-block (BD Bioscience), and 
stained with biotinylated (EZ-Link Sulfo-NHS-LC-Biotin, 
Thermo Fisher) human IgG1 clones at 2 μg/ml for 2 hrs at 
room temperature. Binding was detected with Vectastain 
elite ABC HRP kit (Vector Laboratories) and DAB 
Substrate kits (Vector Laboratories) and subsequently 
counterstained with Mayer’s haematoxylin and viewed 
using a light microscope (Reichert Polyvar 2 type 302001, 
Leica). Results were evaluated by scoring the binding: 0, 
no staining; 1, low amount of staining; 2, intermediate 
staining and 3, high staining.  
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2.8 Statistical analysis 
For statistical analysis, Prism (Graphpad) was used to 
assess for differences between groups and for correlations 
between measurements. Mann-Whitney test was used for 
comparing two groups and Spearman correlations were 
used for evaluation of correlation between measurements 
as indicated. P-values <0.05 were considered statistically 
significant. 
 
2.8 Immunoglobulin gene analysis and structure 
modeling of antibody variable regions 
The V-(D)-J genes of the immunoglobulin variable regions 
of isolated B cells were evaluated using the V-QUEST or 
IgBLAST web tools, where the closest germline and 
mutation rate was determined by comparison to the 
international Immunogenetics information (IMGT) database 
for human immunoglobulin genes [40]. Models of the 
variable region encoded surfaces from the selected clones 
were generated with Prediction of Immunoglobulin 
Structure (PIGS) web server [41], using the best H and L 
chain method. Illustrations of the structures were 
generated in Jmol: an open source Java viewer for 
chemical structures in 3D (http://www.jmol.org/). Molecular 
electrostatic potential (MEP) calculations were calculated 
with the PDB2PQR server [42] and Jmol MEP surface 
using RWB color scheme (scale -0.5, 0.5). 
	
3. Results 
3.1 MDA-modified proteins are present in the joint of 
RA patients 
Citrullinated proteins have previously been identified in RA 
synovial tissue using mass spectrometry [30] and in the 
current study we investigated whether MDA-modified 
proteins are also locally generated during pathogenesis. 
The same seven patient samples were re-analyzed, with 
identification of MDA-modified peptides in the synovial 
extracts by MS/MS analysis. After initial data-filtering and 
high accuracy validation, in total 29 MDA-peptides were 
identified from 10 different MDA-modified proteins (Table 1, 
Supplemental Table 1, Supplemental Figure 1). Examples 
of MDA-modification were found on all amino acids with 
amine or amide groups (i.e. lysine, asparagine, glutamine, 
histidine and arginine). A range of MDA-modified proteins 
were detected, which included high abundant serum 
proteins (i.e. albumin, hemoglobin, IgG gamma chain, and 
transferrin), but also the lipid metabolism associated 
apolipoprotein A1, the acute phase protein a1-
glycoprotein-1, and the enzyme carbonic anhydrase-1. We 
also identified MDA-modification of the cytoskeletal 
proteins actin and vimentin, in our RA samples. 
Intriguingly, two vimentin peptides (440-445 and 446-466) 
and an actin peptide (62-68) have previously been reported 
also undergo citrullination at the same arginine position 
that was now detected as MDA-modified [30]. In the seven 
different synovial samples, we observed large differences 
in the detected abundance of MDA-modification, ranging 
from high level to intermediate, and no detection. While the 
highest levels were seen in two ACPA seropositive RA 
patients, MDA-modification was also detected in the ACPA 
seronegative patient samples. While a number of synovial 
proteins were found to be MDA-modified in the RA joint 
including proteins that are also found to be citrullinated, the 
level of citrullination did not correlate with the level of MDA-
modification, and the patients with highest MDA-detection 
were not the same patients with high levels of citrulline-
modification [30]. 
 
3.2 IgG and IgM anti-MDA are increased in rheumatoid 
arthritis  
To consider the relevance to autoimmune pathogenesis we 
investigated the reactivity of patient serum antibodies with 
MDA-modified self-proteins. Studies of 162 RA, 25 
psoriatic arthritis (PsA), and 30 osteoarthritis (OA) patients, 
and 71 healthy controls, demonstrated that levels of IgG 
anti-MDA were significantly elevated only in patients with 
PsA (p=0.01) and RA (p<0.0001), compared to controls 
(Table 2, Figure 2). Similarly, IgM anti-MDA levels were 
significantly higher in PsA (p=0.006) and RA (p<0.0001). 
While healthy individuals had detectable levels of IgM anti-
MDA antibodies, the levels of IgG anti-MDA were low or 
undetectable in these subjects.  
Taken together, the immune dysregulation in RA patients 
was preferentially associated with elevated levels of 
autoantibodies to MDA-modified self-proteins, while levels 
of natural antibodies to other determinants (e.g. 
phosphorylcholine) may not show the same patterns.  
 
3.3 IgG and IgM anti-MDA are elevated in new onset RA 
compared to established disease 
In the initial analysis, we compared IgG anti-MDA 
responses in patients with new onset RA (NORA) disease, 
defined by less than six months’ disease duration, to early 
RA (ERA), defined by disease duration between six 
months and two years, and to patients with chronic RA 
(CRA), with greater than two-year disease duration 
(Supplemental Figure 3). Particularly, we found the NORA 
patients had significantly higher levels of IgM anti-MDA 
(68±74 RU/ml vs 35±40 RU/ml, p=0.008) and IgG anti-
MDA (21±13 RU/ml vs 10±8 RU/ml, p<0.0001), than CRA 
patients (Table 3). Significantly, the NORA patients had 
significantly greater disease activity than the CRA patients 
(DAS28 5.7±1.2 vs 4.8±1.5, p=0.01) and we could detect a 
direct correlation of IgG anti-MDA with DAS28 scores 
(p=0.0001, Spearman R=0.38).  
To consider the potential effect of treatment, it is important 
to note that the NORA patients had not received any 
disease-modifying antirheumatic drugs (DMARDs), while 
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the patients with established chronic disease were 
receiving standard of care DMARD treatment. For the 19 
NORA patients, we evaluated levels of anti-MDA in serum 
samples obtained at two different time points, separated by 
2-4 weeks, but there were no significant differences 
between these matched samples (Supplemental Figure 4). 
However, seven of these patients receive treatment with a 
synthetic DMARD (methotrexate, corticosteroids and/or 
plaquenil) between the first and second visit, and in these 
samples, the second time point displayed significantly 
reduced levels of IgG anti-MDA antibodies compared to the 
first time point, in paired analysis (p=0.04).  
 
3.4 IgG anti-MDA levels are markers of inflammation in 
DMARD naïve patients 
To directly explore the relationship between inflammation 
and the anti-MDA antibody response, we further studied a 
separate cross-sectional cohort of RA patients that had 
never received DMARD treatment (i.e. DMARD naïve) 
(Supplemental Figure 3, Table 4). In this cohort, there was 
also a significant albeit weak correlation for IgG anti-MDA 
with DAS28 (n=62, Spearman R=0.29, p=0.03). When 
comparing ERA and CRA DMARD naïve patients with 
similar disease activity by DAS28, there were no significant 
differences in IgG anti-MDA levels. Similarly, there were no 
differences in IgG anti-MDA between DMARD naïve CRA 
patients compared to CRA patients receiving standard of 
care DMARD treatment, in two groups with similar mean 
DAS28 scores (Supplemental Table 3, Supplemental 
Figure 5). In summary, the higher levels of IgG anti-MDA 
antibodies that were found in NORA compared to CRA 
patients may primarily reflect an association with higher 
disease activity. Yet, the ERA patients in the DMARD 
naïve cohort also had a longer disease duration (1-2 years) 
compared to the NORA patients (<6 months), so we cannot 
completely exclude effects that reflect the duration of 
symptomatic disease. However, we hypothesize that IgG 
anti-MDA correlates with elevated inflammation associated 
with active disease. We therefore proceeded to analyze 
inflammation-related biomarkers and measurements in the 
DMARD naïve patients.  
From the analyses of 62 DMARD naïve patients, we found 
significant direct correlations between serum levels of IgG 
anti-MDA and the pro-inflammatory cytokines IL-17F, IL-6, 
and TNF-alpha (p=0.05, Spearman R=0.26; p=0.03, 
Spearman R=0.27; p=0.002, Spearman R=0.39, 
respectively; Table 5). Furthermore, higher levels of IgG 
anti-MDA also significantly correlated with raised 
erythrocyte sedimentation rates (ESR) and C-reactive 
protein levels (CRP) (p=0.002, Spearman R=0.39; 
p=0.003, Spearman R=0.37, respectively). However, the 
DAS28 measurement used in our studies incorporated 
ESR measurements, and only CRP can therefore be 
considered an independent variable. As IgG anti-MDA are 
increased in parallel to pro-inflammatory cytokines, we 
interpret our findings as evidence that levels of these 
antibodies are indeed a direct reflection of systemic 
inflammation.  
 
3.5 Serum IgG anti-MDA levels correlate with clinical 
disease activity 
Based on the above-described correlations between IgG 
anti-MDA and disease activity, we repeated these analyses 
in the complete RA cross-sectional cohort. Indeed, 
significantly elevated serum levels of IgG anti-MDA 
antibodies were observed in patients with moderate 
disease (DAS28 3.2-5.1) as well as in patients with high 
disease activity (DAS28>5.1), compared to patients with 
low disease or in DAS remission (DAS28<3.2) (Table 6, 
Figure 4). A significant direct correlation was observed 
between IgG anti-MDA levels and DAS28 score (p<0.0001, 
Spearman R=0.36). There was no correlation between 
DAS28 and IgG anti-CCP3 levels (Supplemental Figure 6). 
Indeed, IgG anti-MDA levels did not significantly correlate 
with serum IgG anti-CCP3, although IgG anti-MDA 
generally appeared to be higher expressed in a subset of 
anti-CCP- and/or RF-seropositive patients (Supplemental 
Figure 6). Although there were weak correlations between 
IgA anti-MDA and IgA anti-CCP3 levels (R=0.29, p=0.02) 
and similarly between IgM anti-MDA and IgM anti-CCP3 
levels (R=0.30, p=0.008).  
To evaluate IgG anti-MDA reactivity as a potential disease 
activity biomarker, we found the odds ratio for high DAS28 
(>5.1) for a positive anti-MDA IgG test (with a cutoff of 15 
RU/ml) was 2.4 (Fisher’s exact test CI:1.2-5.1, p=0.02) with 
sensitivity of 80%, although the specificity only reached 
36%. These associations were explained by the fact that 
only a subset of 28% of RA patients in this cross-sectional 
cohort had significantly elevated IgG anti-MDA 
autoantibodies. We speculate that the associations 
between elevated anti-MDA autoreactivity with more active 
disease may reflect a higher level of inflammation and 
oxidative stress. In turn, this increased burden of MDA 
modified proteins, generated either locally or systemically, 
could contribute to the triggering of anti-MDA immune 
responses. On the other hand, these correlations with 
elevated serum levels of autoantibodies do not necessarily 
reflect an active causal role of MDA-reactive B cells in RA 
pathogenesis.  
 
3.6 Anti-MDA reactive B cells are prevalent in the RA 
joint 
To directly investigate whether MDA-specific responses are 
involved in the pathogenesis of rheumatoid synovitis, we 
isolated single B cells reactive with MDA-modified proteins 
from synovial infiltrates from active RA patients. From the 
synovial B cells of eight ACPA seropositive and two ACPA 
seronegative RA patients (Supplemental Table 4), the 
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antibody gene rearrangements were amplified, cloned, and 
then expressed as recombinant IgG1 monoclonal 
antibodies (mAbs) that were subsequently screened for 
MDA-reactivity by ELISA. Among 114 memory B cell- and 
86 plasma cell-derived mAbs, significant MDA-reactivity 
was detected in six clones; four memory cell-derived and 
two plasma cell-derived mAbs (Figure 5; Supplemental 
Figure 8, Table 7). All of the MDA-reactive antibodies from 
memory B cells were isolated from ACPA seropositive 
patients. However, intriguingly, the antibodies from plasma 
cells with the highest MDA-reactivity were isolated from B 
cells from a seronegative RA patient.  
These anti-MDA mAbs were then evaluated for binding 
reactivity with other types of non-enzymatic 
posttranslational modifications by ELISA (Figure 5-6, 
Supplemental Figure 8). Two out of four memory B cell-
derived mAb clones demonstrated weak binding with 
carbamylated BSA, while one of the two plasma cell-
derived clones showed polyreactivity with a range of the 
control antigens. These mAbs were also extensively 
evaluated for possible citrulline-reactivity with a multiplex 
antigen microarray containing citrullinated peptides, as 
previously described [38], as well as by CCP3 ELISA test. 
The MDA-reactive clones neither showed significant 
binding reactivity with citrulline-containing ligands 
(Supplemental Figure 9), nor did the previously identified 
ACPA mAbs cross-react with MDA modified ligands 
[33](Figure 5-6). Similarly, the MDA-reactive clones also 
did not display detectable RF activity, as measured by 
rabbit IgG binding ELISA. Conversely, the strong RF-
expressing B-cell clones displayed little or no reactivity with 
MDA-modified ligands by ELISA (Figure 5, Supplemental 
Figure 10).  
In summary, three antibody clones (146+:01G07, 
1276:01F04 and 1362:03H05) were found to be highly 
specific for MDA-modified epitopes and were devoid of 
cross-reactivity with citrullinated, carbamylated, 4-HNE-
modifed or phosphorylcholine-containing antigens. These 
antibody clones were derived from different synovial B cell 
subsets; with one originating from an FcRL4+ IgA+ clone 
(146+:01G07), one from an IgG1+ memory B cell 
(1276:01F04), and the other from an IgG1-secreting 
plasma cell (1362:03H05). Importantly, the antibody clones 
recognized MDA-adducts independent of the protein 
context, and also displayed a specific binding reactivity 
with MDA-modified human albumin, MDA-modified 
fibrinogen, MDA-modified histone 2B and MDA-modified 
vimentin, in addition to MDA-modified bovine albumin 
(Figure 6). While the 1276:01F04 showed consistently 
strong reactivity to all tested MDA-modified antigens, 
146+:01G07 (Figure 6) and 1362:03H05 (data not shown) 
had weaker binding and possibly a more preferential 
binding specificity for albumin and vimentin, although this 
could reflect differences in saturation level between these 
mAbs. Similarly, these monoclonal antibodies, which 
displayed strong binding to MDA-oxidized human low 
density lipoprotein (MDA-LDL), had no binding reactivity 
with native LDL (Supplemental Figure 11). Collectively, 
these novel findings suggest a high representation of MDA-
reactivity among synovial memory B cells (3.5%, 4/114) 
and synovial antibody secreting cells (2.3 %, 2/84), and 
highly specific anti-MDA autoreactive B cells therefore 
appear to be prevalent at the primary site of disease in this 
autoimmune disease.  
 
3.7 Strong MDA-binding in close-to-germline encoded 
synovial antibody 
The antibody gene nucleotide sequences of the isolated 
synovial anti-MDA mAbs were analyzed in comparison to 
their closest V-(D)-J germline sequence in the IMGT 
database, and if they had more than two nucleotide 
mismatches in either the heavy or light chain they were 
determined to have somatic hypermutations. Interestingly, 
the B cell clone, 1276:01F04, which was isolated from an 
IgG1-bearing synovial memory B cell, displayed the 
strongest level of reactivity in all MDA-binding assays, was 
encoded by close-to-germline configuration variable gene 
rearrangements (≤2 mismatches in heavy and light chains: 
VH4-39*01 had one replacement mutation; VL1-51 had two 
silent mutations, Table 7). Furthermore, in the light chain 
variable region, these two silent mutations are near the 5’ 
end of the variable region gene and are likely to have 
arisen from the PCR primer used for the cloning method. In 
the heavy chain variable gene, the single nucleotide 
mutation from the closest known germline gene encodes 
for an amino acid A to V replacement mutation in the third 
complement determining region, CDR3, (HCDR3: 
ARVRGYFDY => VRVRGYFDY), which could represent 
unknown allelic variation, the effect of untemplated N 
addition(s), or possibly an error introduced by PCR. While 
this could reflect somatic hypermutation, this conservative 
change may not in any case affect the specificity or 
strength of the binding interaction. Nevertheless, in light of 
these very minor sequence variations we speculate that 
this antibody is derived from the natural antibody pool. Our 
findings are also consistent with an earlier report that 
MDA/MAA-reactive B cells in human umbilical cord blood 
are enriched in the representation of VH4-39*01 
rearrangements [26]. Yet, all the other isolated synovial 
anti-MDA clones displayed changes consistent with 
extensive somatic hypermutation, with 6-18 mutations in 
either the light chain or heavy chain, which may suggest 
they had undergone affinity maturation. 
The 1276:01F04 mAb exhibited strong MDA-ELISA 
reactivity even at low concentration (<50 ng/ml IgG1), and 
the binding was specifically inhibited by soluble MDA-
modified protein in competition experiments (Figure 6). The 
capacity for inhibition of binding was modulated by the 
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degree of MDA-modifications, whereas BSA subject to 24 
hr modification was a stronger inhibitor than MDA-BSA 
generated by 2 hr treatment. Similarly, addition of 
acetaldehyde to the MDA reaction (i.e. MAA) generated an 
antigen with stronger interaction with 1276:01F04. MS 
analysis reveals that the in vitro MDA-modified proteins 
without addition of acetaldehyde, still display chemical 
structures associated MAA (i.e. MDHDC) that increased 
with higher in vitro modification times, presumably due to 
spontaneous breakdown of the excess MDA to 
acetaldehyde, along with subsequent MAA reactions 
(Supplemental Table 2, Supplemental Figure 1 and 12). 
Hence, this mAb may preferentially bind to MAA-type 
structures although our studies cannot absolutely rule out 
binding to the major MDA-adduct N-e-(2-propenal)-lysine. 
SDS-PAGE and Western blot analysis of different MDA-
modified protein batches revealed a low but detectable 
level of aggregation and possible intermolecular cross-
linking in our in-house generated lots. However, 
1276:01F04 showed specific binding to all MDA-
modifications and especially strong binding to the 
monomeric 24 hr treated MDA-BSA fraction (Supplemental 
Figure 12).  
With molecular modeling tools, we studied the predicted 
structure of the antibody variable regions. 1276:01F04 
demonstrated a central groove-like structure formed by the 
surface generated by the heavy and light chain CDR-loops 
(Figure 7). While it is not possible to know the true antigen-
binding surface without the solved structure of the 
antibody-antigen complex, based on the model we 
speculate that the antibody may also have the capacity to 
recognize larger structures, and in addition to these small 
molecule modifications that are about the size of an amino 
acid side chain. By contrast, modeling of the mAb clone 
146+:01G07 revealed a deep pit-like deep structure, which 
may suggest a smaller potential binding-surface. While 
high local hydrophobicity or long extended loops or have 
been implicated in antigen-binding sites with polyreactivity 
[43], 1276:01F04 instead has a rather short HCDR3 and is 
devoid of such structural features.  
In general, all the anti-MDA monoclonal antibodies 
displayed substantial solvent exposed positively charged 
surfaces, with 146+:01G07 and 1362:03H05 having more 
charge than 1276:01F04. This was also reflected in 
somewhat higher estimated isoelectric point for the 
variable region (VL-VH) of 146+:01G07 and 1362:03H05 
(9.3 and 9.1) compared to 1276:01F04 (8.8). However, 
despite the charged surface, these mAbs did not display 
polyreactivity to the prototypic polyanionic macromolecule, 
native dsDNA (data not shown). In general, these B cell 
clones with high specificity for MDA/MAA modifications, 
which were recovered from the RA synovium, display 
features that are commonly associated with the natural 
antibody pool.  
3.8 Differential tissue binding activity of synovial B 
cell-derived mAbs  
To investigate the relevance of the MDA reactive 
antibodies to RA pathogenesis, we performed 
immunohistological staining studies with human synovial 
tissue. Both the close-to-germline clone 1276:01F04 and 
the hypermutated monoclonal 146+:01G07 recognized 
antigenic targets present in the RA inflamed joint (Figure 
8). However, their staining patterns were different, as 
regions in some tissue samples were strongly reactive with 
1276:01F04 while others were more strongly reactive with 
146+:01G07. Nevertheless, the clone 146+:01G07 had 
generally higher reactivity with these sections despite our 
above-described findings of lower reactivity with in vitro 
MDA-modified proteins. We also evaluated for staining of 
healthy synovial tissue, with tissue from RA patients or 
disease controls, including patients with 
spondyloarthropathy, osteoarthritis, and psoriatic arthritis. 
As a control, we compared the staining activity of synovial 
monoclonal antibody devoid of MDA- or ACPA activity. 
While this control monoclonal antibody also showed 
moderate binding to patient materials, the two anti-MDA 
mAbs generally had higher binding to all three synovial 
types. These findings are consistent with the in vivo 
generation of a range of MDA-related antigens during 
synovial pathogenesis, with variations in their recognition 
by different mAbs representative of the immune response. 
 
3.9 Effects of anti-MDA mAbs on in vitro 
osteoclastogenesis 
To evaluate the potential pro-inflammatory properties of 
anti-MDA antibodies, we studied the functional effect of 
anti-MDA mAb exposure in monocyte-derived human 
osteoclast cultures. In these assays, osteoclasts were 
generated from CD14-positive blood monocytes by 
stimulation with M-CSF and sub-optimal concentrations of 
RANKL, with or without the presence of IgG mAbs. We 
observed that the two hypermutated anti-MDA clones 
1362:03H05 and 146+:01G07 robustly enhanced 
osteoclastogenesis. A significant increase in both the 
number of TRAP-positive multi-nucleated cells, as well as 
the level of bone resorption on synthetic calcium 
phosphate surfaces, was demonstrated with the mAbs 
compared to control conditions (Figure 8, Supplemental 
Figure 13). In contrast, the clone 1276:01F04 had no 
detectable effect on osteoclast differentiation. Taken 
together, these functional assays suggest that only the 
hypermutated anti-MDA IgG clones enhance 
osteoclastogenesis in assays designed to evaluate 
properties of antibodies that may contribute in vivo to joint 
destruction.     
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4.	Discussion	
Our studies reveal that MDA carbonylation-modified 
proteins are present in the RA synovium during active 
disease, and that RA patients have elevated levels of 
autoantibodies to these oxidation-associated protein 
modifications, especially at onset of disease, and that anti-
MDA levels correlate with disease activity. Furthermore, a 
high frequency of MDA-specific B cells was found in the 
synovium of RA patients with active disease, and our data 
suggests that some anti-MDA IgG, but not others, may 
contribute to pathogenesis by enhancing the generation 
and activity of osteoclasts. We hypothesize that anti-MDA 
B cells may be selected within the joint due to interactions 
with the high local increased burden of ROS and MDA-
modified proteins that arise in this disease milieu.  
MDA-modification can lead to intra- and inter-molecular 
cross-linking of proteins and change their physical and 
functional properties. IgG antibodies to these modified 
proteins may have pro-inflammatory properties due to their 
effector functions and enhancing danger-signal of 
MDA/MAA, while IgM antibodies may be more likely to 
facilitate blocking and removal of potentially harmfully 
altered proteins. Free MDA can also react with 
acetaldehyde and together form MAA-type of modification 
of proteins. This has been observed to occur in alcoholic 
liver disease, cardiovascular disease, in cigarette smoking, 
and has also recently been shown in staining of RA 
synovial tissue [44-47]. MAA-adducts can contribute to 
airway inflammation and stimulate IL-8 production, and 
MDA-adducts have been shown exaggerate autoimmunity 
and IL-17 cell activation in murine models [48, 49]. Hence, 
MDA- and MAA-adducts may have pro-inflammatory 
properties in the context of RA. It is important to emphasize 
that, even though citrullination, being an enzymatic 
posttranslational modification, is regulated distinctly 
differently than ROS-associated modifications, for example 
neutrophils have the capacity to mediate both types of 
modifications. In fact, the pathway for generation of 
neutrophil extracellular traps (NETs), a process that has 
been implicated in the RA pathogenesis, involves both 
ROS release and PAD4-mediated citrullination [50]. Hence, 
in a setting of chronic inflammation, citrullination and 
MDA/MAA-modification could simultaneously arise. This 
was confirmed by the presented mass spectrometry 
analysis of RA synovial tissue. We speculate that the two 
different types of modifications could also occur within the 
same protein molecule. Hence, MDA-positive B cells could 
in theory act as potent antigen-presenting cell which also 
facilitate epitope spreading and activation of anti-citrulline 
reactive T-cells. The proportion of B cells with natural 
autoreactivity for oxidation-associated modification in the 
circulation are presumably highly represented due to a 
positive selection pressure rather than negative for these 
innate-like B cell populations (i.e. B-1 and marginal zone B 
cells), as demonstrated for other natural autoreactivites in 
murine models studying [51]. The threshold for selection 
and expansion of IgG anti-MDA/MAA B cells may therefore 
be lower than for disease-specific IgG to other 
autoreactivity-associated modifications, such as 
citrullination. 
In the current studies, we have focused on MDA-reactivity 
rather than MAA-adduct reactivity since a lower degree of 
modifications may occur more frequently under 
(patho)physiological conditions. However, antibody 
reactivity to MDA-adducts, compared to MAA-adducts, can 
be hard to distinguish with absolute confidence. A more 
extensive cross-sectional study demonstrated an increase 
of anti-MAA reactivity in RA, which associated with ACPA 
positivity without any direct cross-reactivity between the 
MAA and citrulline distinct epitope bindings [52]. These 
important data have opened up a discussion about 
oxidization-associated antigens in RA [53], and the results 
are in-line with our observation that synovial anti-MDA 
antibodies can have high specificity for MDA-modifications 
whilst showing no reactivity to other oxidation associated 
carbonylation, such as 4-hydroxynonenal (4-HNE), nor to 
carbamylated or citrullinated proteins.  
Importantly, we demonstrate that anti-MDA antibodies bind 
specifically not only to the surrogate antigen MDA-BSA, but 
also to other more RA-relevant modified proteins such as 
MDA-histone, MDA-fibrinogen and MDA-vimentin. Other 
studies have suggested that certain murine or human 
natural antibody clones that bind MDA modified low-density 
lipoprotein (LDL) have the ability to cross-react to 
Porphyromonas gingivalis Gingipain protein, or to 
carbamylated epitopes [54, 55]. The reported phage 
display selected human carbamyl/MDA cross-reactive 
clones had some similarities with the 146+:01G07 with 
unmuted VH3-33/3-30 gene usage although 146+:01G07 
showed no carbamylated-protein reactivity. Similarly, the 
anti-MDA synovial B cell clone 1276:01F04 shows 
similarity in VH gene usage with previously reported cord 
blood anti-MAA natural antibodies that had a high VH4-
39*01 bias [26]. Natural IgM immunity to oxidation-
associated MDA adducts, especially in oxLDL, has been 
extensively studied for their protective properties in 
atherosclerosis [18, 26] (reviewed in [13, 27]), but their 
relation to inflammation-associated IgG anti-MDA is not 
well known. Natural antibodies have been defined as 
primarily spontaneously secreted IgM (and IgA), part of T-
cell independent responses, and are considered to be 
primarily produced by innate-like B-1 cells with limited BCR 
repertoires and (near) germline encoded variable regions 
[56]. Yet a recent study suggested that anti-MDA antibody 
production can, at least to some extent, be T-cell 
dependent [57], and therefore may not be solely produced 
by innate-like B cells. Although B-1 cells are also able to 
interact with T cells as antigen presenting cells [58], and 
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human B-1 cells may also at time undergo isotype class 
switch [59].  
Intriguingly, the synovial anti-MDA B cell clone 1276:01F04 
had significantly stronger binding than any other clone, and 
was generated from an IgG1-bearing memory B cell. The 
high reactivity yet close-to-germline encoded variable 
regions is also consistent with the notion that this antibody 
is from a natural antibody producing B cell. Importantly, this 
particular antibody clone was devoid of pro-inflammatory 
properties in the in vitro osteoclast assay. In contrast, our 
other two MDA-specific clones, 146+:01G07 and 
1362:03H05, had somatic hypermutations (in the case of 
146+:01G07 only in the light chain), and displayed different 
binding patterns compared to 1276:01F04, with lower 
reactivity and possibly a preference for modified albumin 
and vimentin. Both types of antibodies showed binding to 
human synovial tissue samples, although the binding 
patterns were somewhat divergent and the 146+:01G07 
clone generally had higher reactivity. We postulate that 
these represent a distinctly different class of anti-MDA 
reactivity, and future studies are needed to further 
characterize the molecular basis for antigen recognition 
beyond what we were able to detect in our limited assays.  
Recent studies have demonstrated that anti-citrulline IgG 
may have previously unsuspected direct functions in the 
pathogenesis of arthritis by mediating bone destruction and 
pain induction [60-62]. One of the key events in this 
process is ACPA-mediated stimulation of 
osteoclastogenesis and IL-8 production [61, 62]. We 
speculate that some of these same properties may also be 
associated with pathogenic anti-MDA antibodies. 
Importantly, our results show that, certain hypermutated 
low-reactivity type, but not the natural antibody high-
reactivity type, anti-MDA modified protein antibodies have 
the ability to significantly enhance osteoclast differentiation. 
Interestingly, osteoclast stimulating properties were seen in 
the 146+:01G07 mAb that originates from a FcRL4+ 
RANKL overexpressing, potentially pathogenic, B cell 
subset [31]. The level of this stimulation was similar to what 
has previously been observed for polyclonal anti-CCP2 
ACPA. Importantly, we do not see neither anti-MDA 
reactivity in the polyclonal anti-CCP2 pool nor any 
citrullinated peptide reactivity of the anti-MDA antibodies 
(Supplemental Figure 13) suggesting that these are 
parallel reactivities.  
These antibodies may have a more preferential reactivity to 
MDA-vimentin than other antigens and low but significant 
cross-reactivity with full-length citrullinated and native 
vimentin protein. Vimentin has been proposed as a 
potential pathogenic target recognized by ACPA on 
osteoclast [60] and is a well validated object of synovial 
citrullination [30, 63]. We can now also verify that vimentin 
is MDA-modified in the joint. It is intriguing that osteoclast 
differentiation is dependent on both mitochondrial ROS 
activation and PAD citrullination [61, 64] and that this may 
result in parallel protein modifications, alteration of protein 
functions, and pro-inflammatory antigen exposure. In 
conclusion, the similarities and differences between ACPA 
and anti-MDA induced osteoclastogenesis, as well as the 
pathogenic differences between IgG clones within the 
groups, merits further more extensive investigation. 
However, we speculate that it may be possible that IgG 
autoantibody-targeting the same antigen by different 
epitope-interactions and subsequently engaging activating 
Fc receptors or other stimulatory pathways could provoke 
the same downstream pathogenic response. Appreciation 
of the contribution of anti-MDA responses to RA 
pathogenesis may provide an additional reasons for the 
development of therapeutic regiments that restores 
physiologic immune tolerance [65]. Still, it is important to 
acknowledge that elevated anti-MDA autoreactivity is not 
unique to RA but also seen in other autoimmune diseases. 
An increase in anti-MDA in chronic inflammation may 
reflect higher levels of oxidative stress in general. This is in 
concordance with the variation in IgG anti-MDA levels with 
disease activity. Furthermore, not all natural antibody 
reactivities showed the same association. In the clinical 
screenings, we also evaluated antibody reactivity with 
phosphorylcholine (PC), an oxidation-associated lipid head 
group epitope, for which IgM antibody levels are reported 
to directly correlate with atheroprotection [28, 37, 66-68]. 
Both IgM and IgG anti-PC antibody levels were significantly 
higher in RA patients compared to controls. However, in 
contrast to our findings for anti-MDA responses, the 
healthy controls had high relative representation of IgG 
anti-PC antibodies, and no correlation with disease activity 
or pro-inflammatory markers were seen in the RA patients.  
Monitoring disease activity is critical for assessing the 
efficiency of therapeutic options and improving patient 
care. The 28-joint disease activity score, DAS28, which 
incorporates tender and swollen joint counts, the 
physician’s global assessment, and an inflammatory 
marker, (i.e, ESR or CRP) [69], has become widely 
accepted and for many practitioners is the gold standard. 
However, there is a complete absence of consideration of 
the contribution of the dysregulated adaptive immune 
compartment from which this autoimmune disease arises. 
Future investigations of longitudinal cohorts are needed to 
better understand the clinical significance of these 
responses and to potentially refine a more practical and 
relevant biomarker.  
Concluding remarks 
Much is still not known about chronic inflammation, 
oxidative stress, and how autoantibodies and autoreactive 
B cells mediate pathogenesis. Autoreactivity to oxidation-
associated determinants and certain post-translational 
protein modifications are abundant in health, yet these are 
also clearly elevated in disease. Since anti-MDA immunity 
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is part of the natural antibody responses, tolerance may be 
more readily breached in a setting of generalized disease 
associated inflammation and increased immune activation. 
Even though anti-MDA responses are not specific to 
patients with RA, these antibodies may contribute to the 
disease process through immune-complex mediated and 
FcR-engaging pathways involving more classical types of 
polyclonal IgG autoimmune responses. Better 
understanding of the complexity of the adaptive 
autoimmunity in RA may provide new insights in the 
pathogenesis, which will help to develop improved clinical 
disease monitoring tools and more specific and effective 
therapeutic strategies targeting the pathogenic 
autoreactivity.  
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Figure 1. Schematic overview of MDA and MAA adducts  
Malondialdehyde (MDA) can be produced during lipid peroxidation where excess reactive 
oxygen species (ROS) react with polyunsaturated fatty acids in cell membranes or lipid 
containing biomolecules. MDA can covalently modify protein residues with free amine groups 
(i.e. lysine, arginine, histidine and the N-terminus) and to lesser extent residues with amide 
groups (asparagine and glutamine). Here modification of lysine, the most commonly MDA-
modified amino acid, is presented. MDA-modification of lysine generates N-e-(2-propenal)lysine 
groups and can also lead to inter- or intra-molecular crosslinking and 1-amino-3-iminopropene 
adducts. More complex MAA structures are formed if acetaldehyde (AcA) is present in addition 
to MDA (in 1:2 ratio), leading to unstable 2-formyl-3-(alkylamino) butanal (FAAB) adducts or 
stable fluorescent 4-methyl-1,4-dihydropyridine-3,5 dicarbaldehyde (MDHDC) adducts, also 
denoted DHP-lysine residues. Grey, carbon; White, hydrogen; Blue, nitrogen; Red, oxygen. P, 
protein backbone.  
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Figure 2. Anti-MDA autoreactivity is increased in autoimmune disease 
ELISA screening of oxidation-associated autoantibody levels in 71 heathy blood donors, 30 
osteoarthritis (OA), 25 psoriatic arthritis (PsA), and 162 rheumatoid arthritis (RA) patients, 
showed significantly increased levels of IgG and IgM anti-malondialdehyde (MDA) modified 
protein antibodies in autoimmune disease. A, C. Anti-MDA modified protein IgG and IgM, 
respectively. B, D. Anti-phosphorylcholine (PC) IgG and IgM, respectively. MDA-BSA and PC-
BSA were used as screening antigens. P-values were derived from Mann-Whitney analysis.   
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Figure 3. Anti-MDA autoantibody levels are elevated in new onset RA patients compared 
to chronic patients 
Comparison of antibody levels by ELISA serum screening in RA patients with new onset disease 
(NORA, n=34) DMARD naïve patients with less than six-month disease duration, early RA 
patients (ERA, n=7) with more than six months but less than two years of disease duration, and 
chronic RA patients with more than two-years disease duration (CRA, n=56), demonstrates 
higher IgG anti-MDA-modified protein levels in NORA patients but also significantly higher 
disease activity. A. IgG anti-MDA, B. IgG anti-PC, C. IgM anti-MDA, D. IgM anti-PC, E. IgG anti-
CCP3 F. Disease activity by DAS28 ESR. P-values are presented from Mann-Whitney analysis.   
 
Grönwall et al. 2017 
18 
 
 
 
Figure 4. Autoantibodies to MDA-modified proteins are significantly increased in patients 
with active disease 
Analysis of serum antibody levels by ELISA in RA patients with low disease activity (DAS28 
ESR< 3.2, n=14), moderate disease activity (DAS38 ESR 3.2-5.1, n=56) or high disease activity 
(DAS28 ESR>5.1, n=87), showed significantly higher levels of anti-MDA in patients with high 
disease activity. A. IgG anti-MDA, B. IgG anti-PC, C. IgM anti-MDA, D. IgM anti-PC. P-values 
presented from Mann-Whitney analysis. E. Spearman correlation between DAS28 ESR and IgG 
anti-MDA levels. Among the patients with low disease, seven patients were considered to be in 
remission with DAS28<2.6. 
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Figure 5. MDA-reactivity in synovial memory B cells  
ELISA screening of purified recombinant human monoclonal antibodies isolated by single cell 
sorting of RA synovial memory B cells, cloned, and expressed in Expi293 cells as human IgG1. 
A. 114 memory B cell mAbs were screened at 5 ug/ml for binding to MDA-BSA and to control 
wells coated with unmodified BSA. Reactivity was quantified as Relative Units (RU)/ml based on 
a standard reference curve. Antibodies were derived from different synovial subsets: I. CD19+ 
FcRL4+ cells (n=28), II. CD19+ FcRL4- cells (n=20), III. CD19+ IgG + cells from CCP positive 
patients (n=56) IV. CD19+ IgG+ cells from CCP negative patients (n=4). On the right side of the 
panel values for control mAbs (n=8) are shown with two negative controls (1276:01G09, 
1362:01E02) [32], two mAbs with RF activity (146-:01B05, 1276:01C11) [31, 32], two first 
generation pathogenic functional mAbs from memory cells (1276:01D10, 1103:01B02) [32] and 
two plasma cell derived ACPA mAbs (1325:01B09, 1325:04C03). [33] B. Four mAbs showed 
significant MDA reactivity (146+:01G07; 1103:01A03, 1103:01H05, 1276:01F04) and were 
further evaluated for MDA-BSA binding in serial dilution compared to reactivity to the control 
antigen carbamylated BSA (Carb-BSA).  
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Figure 6. High specificity of MDA-reactive synovial memory B cell derived mAbs 
The memory B cell derived recombinant antibody clones 146+:01G07 and 1276:01F04 
demonstrated high specificity for MDA modification and did not bind to 4-HNE modified, 
carbamylated or PC-conjugated BSA. A and B shows serial dilution of mAbs 146+:01G07 and 
1276:01F04, respectively, to different antigen surfaces coated on the same ELISA plate. C. 
Competition assay with soluble antigens. The mAb 1276:01F04 concentration was kept constant 
at 100 ng/ml and analyzed for binding to wells coated with commercial MDA-BSA at 3 ug/ml 
(Academy Bio-Medical) after 15 min 37°C pre-incubation with soluble in-house prepared MDA 
modified BSA with different degree of modification at indicated concentrations. The binding could 
be specifically blocked with MDA-BSA and not with control antigens (native BSA or 4-HNE 
modified BSA) and higher degree of MDA modification (24 hrs prepared MDA-BSA or MAA-
BSA) showed higher inhibition capacity. D and E show binding to MDA-modified human albumin 
(MDA-HSA) MDA-modified human fibrinogen (MDA-Fib), MDA-modified bovine histone 2B 
(MDA-HIS2B) and human recombinant vimentin (MDA-VIM) compared to citrullinated proteins 
(PAD4 citrullinated fibrinogen and histone 2B, rabbit PAD citrullinated vimentin) or control 
treated proteins. The ACPA mAb 1325:01B09 with a preference for citrullinated fibrinogen and 
histone was used as a control for citrullination for fibrinogen and histone 2B and the ACPA mAb 
1325:04C03 with a preference for citrullinated vimentin as control in the vimentin assay. MDA-
modification was performed on the plate with 100 mM MDA for 2 hrs at 37°C. All mAbs were 
tested at 5 ug/ml.   
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Figure 7. Molecular modeling of the structure of variable region anti-MDA specific 
synovial antibodies 
Models are visualized for the VH/VL region of the mAbs 1276:01F04, 146+:01G07 and 
1362:03H05. A. Cartoon model of light chain variable region in red and heavy chain region in 
blue with the light chain CDR loops are highlighted in orange and heavy chain CDR loops in light 
blue. B-C. Solid surface models showing the light chain in red and the heavy chain in blue from 
the side (B) and rotated 90 degrees to show the top (C), looking into the potential antigen 
binding surface built up by the light and heavy chain CDR loops. D. Top view with translucent 
surface revealing a cartoon model of the secondary structure. E. Top view of molecular 
electrostatic potential (MEP) surfaces. The RWB color (scale -.5, .5) shows positively charged 
surfaces as blue and negatively charged as red. Structure models were generated with PIGS 
online tool using best H+L model and visualized with Jmol. Electrostatic calculations were 
calculated with the PDB2PQR server and Jmol MEP.  
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Figure 8. Potential pathogenic properties of IgG anti-MDA is restricted to a subgroup of 
antibodies   
A. Representative results of immunohistochemistry staining of human synovial tissue with two 
anti-MDA mAbs 146+:01G07 and 1276:01F04, compared to a MDA/citrulline-negative plasma 
cell derived synovial monoclonal 1276:06D06 (Control IgG). Images are shown from x25 
magnification. B. Summary of histology results from samples from seven RA patients (five 
seropositive patients and two seronegative patients), three healthy controls and five disease 
controls (including two spondyloarhtritis, one osteoarthritis with Sjögren’s syndrome, and one 
psoriatic arthritis patients). The staining was scored by intensity 1-3 for the three monoclonal 
antibodies. Panels C-E show results of osteoclast stimulation. The monoclonal 146+:01G07 
stimulates increased osteoclastogenesis in cultures of monocyte-derived human osteoclasts 
while the clone 1276:01F04 does not show any functional in vitro properties. Osteoclasts were 
generated in vitro from CD14-positive monocytes isolated from the circulation of healthy donors 
and stimulated to induce osteoclast differentiation with M-CSF and RANKL with or without the 
presence of human purified monoclonal IgG1 at indicated concentrations. C. Fold increase 
osteoclasts measured by counts of tartate-resistant acid phosphatase (TRAP) positive cells with 
≥3 nuclei. D. Fold increase of osteoclasts by resorption area on calcium phosphate plates. The 
graphs show data from average of triplicates from two-four independent experiment using 
osteoclasts cultures from different donors. P-values from student’s t-test are shown. No 
statistically significant difference was seen between 10 μg/ml and 1 μg/ml mAb IgG.  The mAb 
1362:01E02 was used as negative control.  
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Table 1. Identification of malondialdehyde-modified proteins in RA synovial tissue by mass spectrometry 
 
 
 
MDA-modification could be identified on lysine, histidine, arginine, glutamine or asparagine, for a complete list of identified MDA-peptides and 
Mascot scores see Supplemental Table 1.  
 
At least one spectrum per peptide was manually confirmed to be accurate.  
 Number of identified MDA-peptides 
  Syn1 
a-CCP+ RA 
Syn2 
a-CCP+ RA 
Syn3 
a-CCP+ RA 
Syn4 
a-CCP+ RA 
Syn5 
a-CCP+ RA 
Syn6 
a-CCP- RA 
Syn7 
a-CCP- RA 
 Total No        
MDA-proteins with         
Mascot score >13 
        
Actin cytoplasmic 1  1 0 0 0 1 0 0 0 
Alpha-1-acid glycoprotein 1  1 0 0 0 1 0 0 0 
Apolipoprotein A-I  1 0 0 0 1 0 0 0 
Hemoglobin subunit alpha  6 0 0 4 6 0 1 0 
Hemoglobin subunit beta  3 0 0 2 3 0 1 0 
Ig gamma-1 chain C region  1 0 1 1 1 0 1 1 
Serotransferrin  1 0 0 0 1 0 0 0 
Serum albumin  11 0 4 4 8 0 2 2 
Selected MDA-proteins with 
Mascot score <13 
        
Carbonic anhydrase 1  1 0 0 1 1 0 1 0 
Vimentin  3 0 0 0 3 0 2 0 
         Total No:   0 5 12 26 0 8 3 
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Table 2. Anti-MDA and anti-PC natural antibody levels in different patient populations 
 Controls 
(n=71) 
OA 
(n=30) 
PsA 
(n=15) 
RA 
(n=162) 
 Mean±SD Mean±SD p-value# Mean±SD p-value# Mean±SD p-value# 
IgM anti-MDA 13±14 14±12 0.39 25±20 0.006 40±50 <0.0001 
IgM anti-PC 26±28 39±33 0.007 40±40 0.12 55±44 <0.0001 
        
IgG anti-MDA 5±3 7±6 0.06 7±4 0.01 13±11 <0.0001 
IgG anti-PC 28±27 34±28 0.29 36±19 0.10 51±27 <0.0001 
 
# P-values were derived from Mann-Whitney test compared to healthy controls 
OA: osteoarthritis; PsA: psoriatic arthritis, RA: rheumatoid arthritis 
MDA: Malondialdehyde-modification; PC: Phosphorylcholine 
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Table 3. Antibody levels and disease activity in new onset RA compared to chronic RA  
 
 
 
 
 
 
 
 
NORA: Disease onset 0-6 months 
ERA: Disease onset 6 months-2 years 
CRA: Disease onset >2years 
# P-values were derived from Mann-Whitney test 
 
 NORA 0-6m 
(n=34) 
ERA 6m-2y 
(n=7) 
CRA >2y 
(n=56) 
p-value  
NORA vs CRA# 
IgM anti-MDA (RU/ ml, Mean ± SD) 68±74 33±43 35±40 0.008 
IgM anti-PC (RU/ ml, Mean ± SD) 62±49 60±34 52±41 0.44 
     
IgG anti-MDA (RU/ ml, Mean ± SD) 21±13 8±5 10±8 <0.0001 
IgG anti-PC (RU/ ml, Mean ± SD) 49±25 46±19 43±23 0.27 
IgG anti-CCP3 (RU/ ml, Mean ± SD) 359±168 324±323 355±243 0.80 
     
DAS28-ESR (Mean ± SD) 5.7±1.2 4.5±0.7 4.8±1.5 0.01 
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Table 4. Characteristics of the DMARD naïve RA cohort  
 
Characteristics  
Age (years±SD) 46±14 
Females (n, %) 45, 73% 
Ethnicity   
White (n, %) 44, 71% 
African Americans (n, %) 8, 13% 
Asian (n, %) 10, 16% 
Hispanic (n, %) 36, 58% 
ESR (mm; mean±SD) 40±29 
Patient global (mean±SD) 55±27 
DAS28* (mean±SD) 5.6±1.5 
CCP3 IgG pos. (n, %) 54, 87% 
IgM RF pos. (n, %) 53, 85% 
Seronegatives (n, %) 7, 11% 
IgG CCP3 (RU/ml; mean±SD) 355±209 
IgM anti-MDA (RU/ml; mean±SD) 30±36 
IgM anti-PC (RU/ml; mean±SD) 56±49 
IgG anti-MDA (RU/ml; mean±SD) 13±12 
IgG anti-PC (RU/ml; mean±SD) 60±30 
 
Characteristics for 62 DMARD naïve RA patients 
* DAS28 calculations includes ESR 
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Table 5. Association of IgG anti-MDA with inflammatory markers in DMARD naïve RA patients 
 
 Spearman R-value p-value# 
DAS28-ESR 0.29 0.03 
Patient global 0.096 0.51 
ESR 0.39 0.002 
CRP 0.37 0.003 
IL-17F 0.26 0.05 
IL-1b 0.19 0.13 
IL-6 0.27 0.03 
TNF-a 0.39 0.002 
VEGF 0.06 0.68 
IL-6Ra -0.16 0.20 
sTNFRII 0.13 0.28 
 
Correlation analysis for 62 DMARD naïve RA patients 
# P-values were derived from Spearman analysis 
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Table 6. Antibody levels in RA patients with high disease activity compared to low disease activity 
 
 Low/Remission 
DAS28<3.2 
(n=14)* 
Moderate 
DAS28 3.2-5.1 
(n=56) 
High 
DAS28 >5.1 
(n=87) 
   p-value #   p-value #  
DAS28 (mean±SD) 2.6±0.2 4.3±0.5 <0.0001 6.4±0.8 <0.0001 
      
IgM anti-MDA (RU/ml; mean±SD) 22±18 32±34 0.23 48±60 0.15 
IgM anti-PC (RU/ml; mean±SD) 47±33 47±31 0.98 61±52 0.51 
      
IgG anti-MDA (RU/ml; mean±SD) 6±3 12±11 0.005 15±12 0.001 
IgG anti-PC (RU/ml; mean±SD) 52±27 51±25 0.95 51±29 0.88 
IgG anti-CCP3 (RU/ml; mean±SD) 344±240 344±203 0.96 364±209 0.87 
 
*Seven patients were in remission DAS28<2.6 and seven patients had low disease activity DAS28 2.6-3.2 
# P-values were derived by Mann-Whitney analysis compared to RA patients with low disease activity/DAS remission 
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Table 7. Characteristics of synovial-derived monoclonal anti-MDA antibodies  
 
CLONE-ID B CELL TYPE a-MDA UNSPEC. VL JL GERMLINE VL (%)  
VL 
MUT. VH DH JH 
GERMLINE 
VH (%)  
VH 
MUT. HCDR3 
1276:01F04 Mem. IgG+ ++++ - LV1-51*01 LJ3*02 99.3 2 4-39*01 3-10*02 4*02 99.7 1 VRVRGYFDY 
146+:01G07 Mem. FcRL4+ IgA+ ++ - KVD3-15*01 KJ2*01 93.5 18 3-33*01 5-24*01 4*02 99.7 1 ARARRGDGYNQARYYYFDY 
1103:01H05 Mem. IgG+ ++ + LV1-40*01 LJ2*01 96.6 10 3-30*01 1-26*01 4*02 100 0 ARDPYRGKATQDY 
1103:01A03 Mem. IgG+ ++ + LV1-51*01 LJ3*02 98.0 6 4-39*01 5-5*01 4*02 97.3 8 ARRRGYSYGYSRARGTTFDY 
1362:03H05 Plasma IgG+ ++ - KV4-1*1 KJ2*01 95.9 12 3-53*01 3-3*02 6*02 95.5 13 ARDRRGWSGYYSLRYGMDV 
1362:07D01 Plasma IgG+ ++ +++ KV1-39 KJ2*01 95.8 12 4-34*1 2-8*01 6*02 95.9 12 AREGTWPPYNYYYFGMDV 
 
FcRL4: Fc Receptor like 4 
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Supplemental Table 1. Identification of MDA-modified proteins in RA synovial tissue by mass spectrometry 
 
MDA modified peptides   MASCOT SCORES 
Accession Description Peptide sequence MDA-
site 
Max 
score 
Syn1 Syn2 Syn3 Syn4 Syn5 Syn6 Syn7 
ACTB_HUMAN1 Actin cytoplasmic 1  RGILTLK (R1) 16.24    16.24    
A1AG1_HUMAN a1-acid glycoprotein 1  NWGLSVYADKPETTK (N1) 47.27    47.27    
APOA1_HUMAN Apolipoprotein A-I  DSGRDYVSQFEGSALGK (R4) 17.35    17.35    
CAH1_HUMAN2 Carbonic anhydrase 1  HDTSLKPISVSYNPATAK (H1) 10.03   10.03 5.77  6.19  
HBA_HUMAN3 Hemoglobin subunit a KVADALTNAVAHVDDMPNALSALSD
LHAHK 
(K1) 21.45   21.45 15.2    
HBA_HUMAN3 LS CLLVTLAAHLPAEFTPAVHASL
DK 
(H4) 24.77    24.77    
HBA_HUMAN3 LRVDPVNFK (R2) 14.23    14.23    
HBA_HUMAN3 TYFPHFDLSHGSAQVK (H5) 15.42   15.42 14.43    
HBA_HUMAN VGAHAGEYGAEALERMFLSFPTTK (R15) 25.08   25.08 13.07    
HBA_HUMAN VGAHAGEYGAEALERMFLSFPTTK (H4) 62.01   36.65 62.01  49.32  
HBB_HUMAN4 Hemoglobin subunit b  KVLGAFSDGLAHLDNLK (K1) 61.51   58.90 61.51  57.49  
HBB_HUMAN LHVDPENFRLLGNVLVCVLAHHFGK (H2) 24.79   24.02 24.79    
HBB_HUMAN5 VVAGVANALAHKYH (N7) 14.49    14.49    
IGHG1_HUMAN  Ig g-1 chain C region  FNWYVDGVEVHNAK (N2) 33.37  19.88 23.61 33.37  30.51 13.75 
TRFE_HUMAN6 Serotransferrin  HQTVPQNTGGK (H1) or 
(Q2) 
16.09    16.09    
ALBU_HUMAN7 Serum albumin  AWAVARLSQRFPKAEFAEVSK (K13) 25.56    25.56  19.26  
ALBU_HUMAN8 FQNALLVRYTK (R8) 32.7   27.09 26.25   32.7 
ALBU_HUMAN8 FQNALLVRYTK (N3) 24.62  24.62      
ALBU_HUMAN8 FQNALLVRYTK (Q2) 23.8    16   23.8 
ALBU_HUMAN8 KVPQVSTPTLVEVSRNLGK (K1) 30.00  18.95 17.35 30    
ALBU_HUMAN8 KVPQVSTPTLVEVSRNLGK Q4) 15.41  15.41      
ALBU_HUMAN8 QNCELFEQLGEYK (N2) 31.79   31.79 31.05  20.32  
ALBU_HUMAN8 QTALVELVK (Q1) 18.72   18.72     
ALBU_HUMAN8 RMPCAEDYLSVVLNQLCVLHEK (R1) 48.51    48.51    
ALBU_HUMAN8 VFDEFKPLVEEPQNLIK (K6) 13.06    13.06    
ALBU_HUMAN8 VHTECCHGDLLECADDRADLAK (H2) 28.22  17.63  28.22    
VIME_HUMAN Vimentin  RTLLIK (R1) 1.83    0.71  1.83  
VIME_HUMAN TVETRDGQVINETSQHHDDLE (R5) 5.22    5.22    
VIME_HUMAN9 VRFLEQQNK (R2) 12.05    2.18  12.05  
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At least one spectrum per peptide was manually confirmed to be accurate. 
Peptides with maximum mascot score less than 13 are highlighted in grey.  
 
Alternative accession numbers: 
1. CTG_HUMAN, ACTA_HUMAN, ACTH_HUMAN, C9JZR7_HUMAN, ACTC_HUMAN, ACTS_HUMAN, Q5T8M8_HUMAN, A6NL76_HUMAN, 
POTEE_HUMAN, POTEF_HUMAN, POTEI_HUMAN, POTEJ_HUMAN, C9JFL5_HUMAN, Q5T8M7_HUMAN, I3L3I4_HUMAN 
2. E5RH81_HUMAN, E5RHP7_HUMAN 
3. G3V1N2_HUMAN 
4.. HBD_HUMAN, E9PFT6_HUMAN 
5. HBD_HUMAN 
6. J3KN47_HUMAN 
7. B7WNR0_HUMAN 
8. B7WNR0_HUMAN, C9JKR2_HUMAN 
9. K22O_HUMAN, K2C8_HUMAN, F8VU64_HUMAN, F8VUG2_HUMAN, K2C7_HUMAN, F8VRG4_HUMAN, K2C6A_HUMAN, K2C6B_HUMAN, 
K2C6C_HUMAN, KRT85_HUMAN, K2C3_HUMAN, J3QST3_HUMAN, K2C75_HUMAN, K2C79_HUMAN, K2C5_HUMAN, KRT84_HUMAN, 
GFAP_HUMAN, B0YJC4_HUMAN, KRT83_HUMAN, KRT81_HUMAN, KRT86_HUMAN, K2C78_HUMAN, F8VZY5_HUMAN, B4DIR1_HUMAN 
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Supplemental Table 2. Mass spectrometry analysis of in vitro modified BSA 
 
MDA modified peptides  MASCOT SCORES* 
Sequence (bovine albumin ALBU_BOVIN) MDA- Site Max score BSA (ctrl) BSA (MDA 2h) BSA (MDA 24h) 
ADLAKYICDNQDTISSK MDA (K5) 21.16  13.28 21.16 
AEFVEVTKLVTDLTK MDA (K8) 51.98  51.98 29.25 
AFDEKLFTFHADICTLPDTEK MDA (K5) 17.44   17.44 
ALKAWSVAR MDA (K3) 17.72  15.29 17.72 
ATEEQLKTVMENFVAFVDK MDA (K7) 20.2  16.42 20.2 
CCAADDKEACFAVEGPK MDA (K7) 38.36  38.36 18.67 
EACFAVEGPKLVVSTQTALA MDA (K10) 14.37   14.37 
FPKAEFVEVTK MDA (K3) 32.73  32.73 20.36 
HLVDEPQNLIKQNCDQFEK MDA (K11) 23.8  23.8  
HPEYAVSVLLR MDA (H1) 13.21   13.21 
KVPQVSTPTLVEVSR MDA (K1) 34.59 17.4 23.81 34.59 
LAKEYEATLEECCAK MDA (K3) 43.53  43.53 36.56 
LCVLHEKTPVSEK MDA (K7) 27.56   27.56 
LSQKFPKAEFVEVTK MDA (K7) 26.28  26.28 20.67 
LVNELTEFAKTCVADESHAGCEK MDA (K10) 23.9  23.9  
NYQEAKDAFLGSFLYEYSR MDA (K6) 22.03  20.34 22.03 
QNCDQFEKLGEYGFQNALIVR MDA (K8) 33.67  13.15 33.67 
QNCDQFEKLGEYGFQNALIVR MDA (K8), Gln->pyro-Glu (N-term Q) 16.67	   16.67 
RHPEYAVSVLLR MDA (R1 or H2) 17.22  13.75 17.22 
RHPYFYAPELLYYANK MDA (R1 or H2) 15.72 15.72   
SLHTLFGDELCKVASLR MDA (K12) 23.32  21.06 23.32 
TCVADESHAGCEKSLHTLFGDELCK MDA (K13) 16   16 
TPVSEKVTKCCTESLVNR MDA (K6), MDA (K9) 15.49  15.49 13.95 
TPVSEKVTKCCTESLVNR MDA (K9) 14.36   14.36 
TVMENFVAFVDKCCAADDK MDA (K12) 17.1   17.1 
TVMENFVAFVDKCCAADDKEACFAVEGPK MDA (K19) 30.04  30.04 21.91 
TVMENFVAFVDKCCAADDKEACFAVEGPK MDA (K12) 17.48  17.48  
TVMENFVAFVDKCCAADDKEACFAVEGPK MDA (K12), MDA (K19) 23.2  23.2 14.76 
TVMENFVAFVDKCCAADDKEACFAVEGPK Oxidation (M3), MDA (K12) 17.52  17.52  
TVMENFVAFVDKCCAADDKEACFAVEGPK Deamidated	(N5),	MDA	(K12) 14.36  14.36  
TVMENFVAFVDKCCAADDKEACFAVEGPK Deamidated	(N5),	MDA	(K19) 26.11   26.11 
VTKCCTESLVNR MDA (K3) 36.91  36.91 31.64 
YICDNQDTISSKLK MDA (K12) 19.29  19.29 13.42 
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MAA modified peptides  MASCOT SCORES* 
Sequence MAA-Site Max score BSA (ctrl) BSA (MDA 2h) BSA (MDA 24h) 
ADLAKYICDNQDTISSK MAA (K5) 27.47   27.47 
ALKAWSVAR MAA (K3) 20.24   20.24 
CASIQKFGER MAA (K6) 18.13   18.13 
CCTKPESERMPCTEDYLSLILNR MAA (K4) 15.01   15.01 
DTHKSEIAHR MAA (K4) 13.65   13.65 
ETYGDMADCCEKQEPER MAA (K12) 43.28   43.28 
KVPQVSTPTLVEVSR MAA (K1) 29.81  17.36 29.81 
LAKEYEATLEECCAK MAA (K3) 25.74   25.74 
LVNELTEFAKTCVADESHAGCEK MAA (K10) 19.66   19.66 
NYQEAKDAFLGSFLYEYSR MAA (K6) 44.6   44.6 
SLHTLFGDELCKVASLR MAA (K12) 24.27   24.27 
TVMENFVAFVDKCCAADDKEACFAVEGPK MAA (K12) 25.35   25.35 
TVMENFVAFVDKCCAADDKEACFAVEGPK Deamidated (N5), MAA (K12) 19.54   19.54 
VTKCCTESLVNR MAA (K3) 32.88   32.88 
 
*limit for significance = 13 
Each column shows the highest score from 4 technical replicate MS analysis. 
At least one spectrum per peptide was manually confirmed to be accurate. 
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Supplemental Table 3. Characteristics of CRA with standard care compare to DMARD naïve CRA 
 
Characteristics CRA  DMARD naïve CRA p-value# 
Age (years±SD) 54±10 50±14 0.44 
Females (n, %) 23, 82% 24, 85% 1.0 
RA duration 15±12 9±8 0.004 
DAS28 5.2±1.6 5.3±1.6 0.79 
CCP3 IgG pos. (n, %) 26, 93% 20, 71% 0.08 
IgM RF (n, %) 26, 93% 20, 71% 0.08 
Seronegative (n, %) 2, 7% 8, 29% 0.08 
IgG CCP3 (RU/ml; mean±SD) 367±237 277±220 0.09 
IgM anti-MDA (RU/ml; mean±SD) 35±34 22±24 0.09 
IgM anti-PC (RU/ml; mean±SD) 54±40 46±42 0.20 
IgG anti-MDA (RU/ml; mean±SD) 10±8 13±13 0.55 
IgG anti-PC (RU/ml; mean±SD) 42±24 55±31 0.12 
 
N=28 in both groups, disease duration > 2 years 
#P-values were derived by Mann-Whitney analysis 
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Supplemental Table 4. Screened antibody clones derived from single cell sorted synovial B cells  
 
Patient Patient status Source of B cells Synovial B cell subset NO of 
screened 
clones 
NO of anti-MDA 
positive clones 
RA146 CCP pos Synovial tissue FcRL4 +  18 1 
RA146 CCP pos Synovial tissue FcRL4 -  11  
RA153 CCP pos Synovial fluid FcRL4 +  10  
RA153 CCP pos Synovial fluid FcRL4 -  10  
RA1003 CCP pos Synovial fluid IgG+ memory 7  
RA1103 CCP pos Synovial fluid IgG+ memory 17 2 
RA1124 CCP pos Synovial fluid IgG+ memory 2  
RA1276 CCP pos Synovial fluid IgG+ memory 20 1 
RA1276 CCP pos Synovial fluid ASC 33  
RA1444 CCP pos Synovial fluid IgG+ memory 7  
RA1444 CCP pos Synovial fluid ASC 9  
RA1325 CCP pos Synovial fluid IgG+ memory 7  
RA1325 CCP pos Synovial fluid ASC 2  
RA0663 CCP neg Synovial fluid IgG+ memory 2  
RA1362 CCP neg Synovial fluid IgG+ memory 3  
RA1362 CCP neg Synovial fluid ASC 42 2 
      
   Total number of screened 
clones: 
200  
 
ACS: Antibody secreting cell; FcRL4: Fc Receptor like 4 
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Supplemental Table 5. Citrullinated peptides in the ISAC microarray 
 
Peptide Protein Amino 
acids 
Amino acid sequence# Reference 
Cit-Fil307-324 Filaggrin 307-324 SHQEST(cit)GRSRGRSGRSGS (cyclic) (1, 2) 
Cit-Vim60-75 Vimentin 60-75 VYAT(cit)SSAV(cit)L(cit)SSVP (3) 
Cit-Vim2-17 Vimentin 2-17 ST(cit)SVSSSSY(cit)(cit)MFGG (4) 
Cit-Fibβ36-52 Fibrinogen β-chain 36-52 NEEGFFSA(cit)GHRPLDKK (3) 
Cit-Fibα563-583 Fibrinogen α-chain 563-583 HHPGIAEFPS(cit)GKSSSYSKQF (5) 
Cit-Fibα580-600 Fibrinogen α-chain 580-600 SKQFTSSTSYN(cit)GDSTFESKS (5) 
Cit-Fibβ(Cit-R)62-81a Fibrinogen β-chain 62-81 APPPISGGGY(cit)ARPAKAAAT (5) 
Cit-Fibβ(R-Cit)62-81b Fibrinogen β-chain 62-81 APPPISGGGYRA(cit)PAKAAAT (5) 
CEP-15-21 α-Enolase 5-21 CKIHA(cit)EIFDS(cit)GNPTVEC (cyclic) (6) 
 
#Citrullinated (cit) peptides used in the Phadia’s ImmunoCAP ISAC microarray system (7) 
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Supplemenatal Figure 1. Identification of malondialdehyde-modified proteins in 
RA synovial tissue by mass spectrometry 
 
The figure depicts Mascot scores for MDA-containing peptides identified by mass 
spectrometry in RA synovial tissue. MDA-modification could be identified on lysine, 
histidine, arginine, glutamine or asparagine, for a complete list of identified MDA-
peptides and Mascot scores see Supplemental Table 1. At least one spectrum per 
peptide was manually confirmed to be accurate. Patient 1-5 were seropositive for 
ACPA and patient 6-7 were seronegative. 
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Supplemental Figure 2. Example of mass spectrometry spectra for 
identification of malondialdehyde (MDA) and malondiadehyde/acetaldehyde 
(MAA) modified peptides.  
 
The figure shows a tryptic peptide from 24h MDA-modified bovine serum albumin 
(BSA), ETYGDMADCCEKQEPER. Three different forms of the peptide was 
identified: unmodified (upper trace in each spectrum), MDA modified (middle trace) 
and MAA (lower trace). A) shows the mass spectrum for the three forms indicating 
the mass shifts of 54.0106 Da for MDA and 134.0368 for MAA. B) shows the shifts in 
retention time for the three different forms. C) show the mass shifts in the fragments 
that contain the modifications. For clarity, only y3 to y12 have been indicated. The 
modified site (K) has been marked in red. All identified modified peptides in the MDA-
modified BSA are presented in Supplemental Table 2.  
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Supplemental Figure 3. Schematic overview of RA patient samples included in 
serological anti-MDA studies 
 
Serological studies and statistical analysis were performed either on the primary RA 
cohort, the secondary DMARD naïve cohort, or the complete cross-sectional RA 
patient cohort.    
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Supplemental Figure 4. Variation of IgG anti-MDA antibody levels over time.  
ELISA screeing of IgG (A, C) and IgM (B, D) anti-MDA serum levels in 19 new onset 
RA patients (NORA) at two differen time points with 2-4 weeks in between. In most 
patients the levels remained relativly constant and there were no significant change. 
However, 7 of these patients did receive DMARD treatment (methotrexate, steroids, 
or plaquenil) between the two time points, presented in panel C-D, and for these 
patients the level of IgG anti-MDA did weakly but significantly decreased. Evaluated 
with paired t-test. 
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Supplemental Figure 5. Anti-MDA autoantibody levels were not significantly 
different in chronic patients with similar disease activity but with or without 
DMARD treatment.  
 
No difference was seen in anti-MDA levels between patient groups in the DMARD 
naïve cohort. A, C. Anti-MDA IgG and IgM in DMARD naïve early RA (ERA, disease 
duration <2yrs, n=24) and chronic RA (CRA, disease duration ≥2yrs, n=28). D, E. 
Anti-MDA antibodies in chronic RA receiving standard care (n=28, DAS28 5.2±1.6) 
and DMARD naïve chronic RA (n=28, DAS28 5.3±1.6). 
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Supplemental Figure 6. Serum anti-CCP3 levels are not associated with 
disease activity by DAS28 
A. Serum anti-CCP3 by ELISA in RA patients with low disease activity (DAS28 ESR< 
3.2, n=14), moderate disease activity (DAS38 ESR 3.2-5.1, n=56) or high disease 
activity (DAS28>5.1, n=87). P-values were derived from Mann-Whitney analysis. B. 
Spearman association between DAS28 ESR scores and IgG anti-CCP3 levels.  
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Supplemental Figure 7. Association of serum levels of IgG anti-MDA with anti-
CCP3 or RF 
 
IgG anti-CCP3 and IgM RF levels were determined by commercial ELISA kits (Inova 
Diagnostics) while anti-MDA IgG, IgM, and IgA as well as CCP3 IgA and IgM were 
measured with in-house ELISAs. Cut-off for positivity when available is marked with a 
dotted line. Cut-off for IgG anti-MDA (15 RU/ml) was determined by values for 
healthy controls (n= Mean + 3SD) while the cut-off for IgG anti-CCP3 (20RU/ml) and 
RF (6RU/ml) was based on the recommendation from the manufacturer of the clinical 
tests used (Inova Diagnostics). A. IgG anti-MDA vs IgG anti-CCP3 B. IgG anti-MDA 
vs IgM RF. C. IgM anti-MDA vs IgM anti-CCP3 D. IgA anti-MDA vs IgA anti-CCP3. 
IgG anti-MDA did not correlate with IgG anti-CCP3. There was a weak significantly 
correlation between IgG anti-MDA levels and RF IgM levels. Similarly, IgA anti-MDA 
correlated with IgA anti-CCP3 and IgM anti-MDA correlated with IgM anti-CCP3.  
 P-values were derived from Spearman correlation analysis.   
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Supplemental Figure 8. Identification of MDA-reactive antibody clones derived 
from synovial plasma cells 
ELISA screening of purified recombinant human monoclonal antibodies isolated from 
synovial antibody secreting cells (ASC) identified by the fluorescent foci method, 
cloned, and expressed in Expi293 cells as IgG1. A. 84 ASC mAbs were screened at 
5 ug/ml for binding to MDA-BSA and to control wells coated with unmodified BSA. 
Reactivity was quantified as Relative Units (RU)/ml based on a standard reference 
curve. Antibodies were derived from different synovial subsets: I. IgG secreting cells 
from CCP positive patients (n=42) II. IgG secreting cells from CCP negative patients 
(n=42). B. Two mAbs showed significant MDA reactivity (1362:03H05 and 
1362:07D01) and further evaluated for MDA-BSA binding in serial dilution compared 
to reactivity to the control antigen carbamylated BSA (Carb-BSA). In the graph the 
ASC mAbs are compared to the memory B cell identified clone 146+:01G07 and 
1376:01F04. The clone 1362:07D01 shows high level of polyreactivity/unspecific 
binding while the clone 1362:03H05 is MDA-specific.   
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Supplemental Figure 9. Synovial anti-MDA mAbs do not bind to citrullinated 
antigens 
 
A. Results from screened using Phadia’s ImmunoCAP ISAC microarray system, 
where antibody binding to a large number of citrullinated peptides and their native 
arginine counterpart were compared (7). A selection of other autoimmunity-related 
antigens was also included. Activity Units (AU) are displayed in the heatmap, 
calculated form the fluorescence intensity by normalization to an internal control. B. 
ELISA screening of monoclonal IgG at 5ug/ml binding to CCP using the QUANTA 
Lite CCP3 assay (Inova Diagnostics). Values were compared to the ACPA mAb 
1325:01B09 and the negative control 1325:01E02. Peptide information can be 
obtained in Supplemental Table 3.  
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Supplemental Figure 10. Synovial anti-MDA mAbs do not demonstrate any 
rheumatoid factor activity. 
 
Rheumatoid factor activity of the monoclonal antibodies was evaluated by ELISA 
using wells coated with rabbit IgG (3 ug/ml) and detection with rabbit (Fab’)2 anti-
human IgG (gamma-specific). Purified recombinant monoclonal IgG1 originated from 
A. synovial memory B cell clones, B. ASC clones, was tested at 5 ug/ml. Values for 
control mAbs (n=8) are shown in A. These included two negative controls 
(1276:01G09, 1362:01E02), two mAbs with RF activity (T13.146-B05, 1276:01C11), 
two first generation pathogenic functional mAbs (1276:01D10, 1103:01B02) and two 
second generation plasma cell derived ACPA mAbs (1325:01B09, 1325:03C03). C. 
RF reactivity of the anti-MDA memory B cell mAbs 1276:01F04, 146+:01G07 in serial 
dilution compared to the RF clone 1276:01C11 (also identified from synovial memory 
B cells). 
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Supplemental Figure 11. Synovial anti-MDA modified protein bind to MDA-LDL 
and not native LDL 
 
The figure depicts ELISA reactivity to MDA-modified human low density lipoprotein 
(MDA-LDL) compared to native unmodified LDL for three human synovial anti-MDA 
reactive IgG clones, 1276:01F04, 146+:01G07, 1362:03H05 and a negative control 
mAb 1362:01E02, at indicated concentrations. 
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Supplemental Figure 12. Different forms of MDA-modified BSA recognized by 
the anti-MDA mAb 1276:01F04 
 
In-house prepared malondialdehyde modified bovine serum albumin, MDA-BSA, was 
prepared by incubating molecular grade BSA with 50 mM MDA for 2hrs, 6hrs or 
24hrs at 37C before extensive dialysis. Addition of 50% acetaldehyde in addition to 
MDA was used for generation of MAA-type modifications. Commercial MDA-MSA (far 
right lane) was used for comparison (Academy Bio-Medical). A. Coomassie blue 
stained SDS-PAGE (4-12% bis-tris gel with MES running buffer) of different lots of 
MDA-modified BSA. B. Western blot analysis of different lots of MDA-BSA stained 
with the monoclonal human recombinant antibody 1276:01F04 at 1 ug/ml. Control 
BSA incubated and treated the same way as modified BSA but without addition of 
MDA/acetaldehyde. The different BSA lots were denatured and reduced before run at 
3 ug/lane. C. Results from mass spectrometry analysis of the untreated BSA 
compared to the BSA that had been MDA-treated for 2hrs or 24hrs. The graph shows 
the mascot scores for peptides identified to contain MDA-modified residues, MDA-
lysine peptides (with N-e-(2-propenal)lysine), MDA-modified arginine, or peptides that 
contained MAA-lysine peptides (with 4-methyl-1,4-dihydropyridine-3,5 
dicarbaldehyde, MDHDC). Note that no acetaldehyde had been added to the 
reaction. The number of identified modified BSA peptides for each condition has 
been indicated. Only peptides with significant mascot score (>13) were included. 
Peptide sequences are presented in Supplemental Table 2.   
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Supplemental Figure 13. Plasma cell derived anti-MDA mAb enhance 
osteoclastogenesis  
 
The synovial plasma cell derived clone 1362:03H05 stimulates increased 
osteoclastogenesis in cultures of macrophage derived human osteoclasts. 
Osteoclasts were generated in vitro from CD14-positive monocytes isolated from the 
circulation of healthy donors and stimulated to induce osteoclast differentiation with 
M-CSF and RANKL with or without the presence of human purified monoclonal IgG1 
at indicated concentrations. A. Fold increase osteoclasts measured by counts of 
tartate-resistant acid phosphatase (TRAP) positive cells with ≥3 nucleai. B. Numbers 
of TRAP positive cells. C. Fold increase of osteoclasts by resorption area on calcium 
phosphate plates. P-values are shown from 2-sided student’s t-test. The mAb 
1362:01E02 was used as negative control. The graph shows means of triplicates of a 
representative experiment. 
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Supplemental Figure 14. Polyclonal anti-CCP2 does not bind to MDA-modified 
protein 
 
The figure depicts ELISA data evaluating binding of polyclonal RA IgG to MDA-
modified protein. A. Reactivity of pooled RA serum (14 seropositive RA patients), 
starting at dilution 1:100. B. Reactivity of affinity purified serum CCP2-reactive IgG 
from seropositive RA patients compared to the IgG flow through from the CCP2 
column. Two independent batches are shown (#1 purified from 35 patients; #2 
purified from 108 patients). Low or no binding above background was seen in the 
polyclonal anti-CCP2, some binding could be seen in one of the CCP2 negative 
fractions (flow through #1). Binding to MDA-BSA was compared to a control surface 
coated with only BSA. Chromopure human polyclonal IgG (Jackson 
ImmunoResearch) was used as negative control. Purification of anti-CCP2 IgG have 
been previously reported (8).  
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